<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4356">
  <stage>Registered</stage>
  <submitdate>18/11/2013</submitdate>
  <approvaldate>18/11/2013</approvaldate>
  <nctid>NCT01997333</nctid>
  <trial_identification>
    <studytitle>Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer</studytitle>
    <scientifictitle>A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)</scientifictitle>
    <utrn />
    <trialacronym>METRIC</trialacronym>
    <secondaryid>CDX011-04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic gpNMB Over-expressing Triple Negative Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CDX-011
Treatment: drugs - Capecitabine

Active Comparator: Capecitabine - Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.

Experimental: Drug: CDX-011 - CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.


Treatment: drugs: CDX-011


Treatment: drugs: Capecitabine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause.</outcome>
      <timepoint>Evaluated every 6 - 9 weeks following treatment initiation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - ORR is defined as the proportion of patients who achieve best overall response of complete or partial response according to RECIST 1.1.</outcome>
      <timepoint>Evaluated every 6 - 9 weeks following treatment initiation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR)</outcome>
      <timepoint>Evaluated every 6 - 9 weeks following treatment initiation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>During treatment and 3 months from end of treatment through end of study or approximately up to 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events (AE) - The percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity.</outcome>
      <timepoint>Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or capecitabine and until discontinuation of follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) - Concentration of the antibody-drug conjugate, total antibody and free MMAE will be determined.</outcome>
      <timepoint>Following 1 dose of CDX-011.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Among other criteria, patients must meet all of the following conditions to be eligible for
        the study:

          1. Diagnosed with metastatic (i.e., cancer that has spread) TNBC

               -  minimal or no expression of estrogen and progesterone receptors (ER/PR) &lt;10% of
                  cells positive by immunohistochemistry

               -  HER 2 staining 0 or 1+ by IHC or copy number &lt;4.0 signals/cell

          2. Documented progression of disease based on radiographic, clinical or pathologic
             assessment during or subsequent to the last anticancer regimen received.

          3. Breast cancer tumor confirmed to express gpNMB. This will be determined by submitting
             a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease
             setting to a central laboratory for analysis.

          4. Received no more than two prior chemotherapy treatments for advanced (locally
             advanced/recurrent or metastatic) breast cancer.

          5. Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin or
             Doxil) if clinically indicated and a taxane (eg: Taxol).

          6. ECOG performance status of 0 - 1.

          7. Adequate bone marrow, liver and renal function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion:

        Among other criteria, patients who meet any of the following conditions are NOT eligible
        for the study:

          1. Progression/recurrence of breast cancer during or within 3 months of completion of
             neoadjuvant or adjuvant chemotherapy.

          2. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are
             moderate (Grade 2) or worse in severity.

          3. Known brain metastases, unless previously treated and asymptomatic for 2 months and
             not progressive in size or number for 2 months.

          4. Significant cardiovascular disease.

          5. Previously received capecitabine and discontinued due to progression or intolerance;
             previously received CDX-011 or other MMAE containing agents.

          6. Active systemic infection requiring treatment. Infection controlled by oral therapy
             will not be exclusionary.

          7. Chronic use of systemic corticosteroids.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>327</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>St. Vincents Hospital Sydney - Darlinghurst</hospital>
    <hospital>Macquarie University - Macquarie Park</hospital>
    <hospital>The Tweed Hospital - Tweed Heads</hospital>
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <hospital>Townsville Hospital - Douglas</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Western Hospital - Footscray</hospital>
    <hospital>Joint Ludwig-Austin Dept of Medical Oncology - Hieidelberg</hospital>
    <hospital>Epworth Health Care - Richmond</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2109 - Macquarie Park</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>2076 - Wahroonga</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3084 - Hieidelberg</postcode>
    <postcode>3121 - Richmond</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hainaut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Vlaams Brabant</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels Capital Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Alpes-Maritimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rhône</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Sarthe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Avignon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Mont de Marsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St Gregoire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wurttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle an der Saale</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Münster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Troisdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pordenone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Asturias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castellón</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Communidad Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Málaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>City of London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Devon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>East Sussex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London, City of</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottinghamshire</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celldex Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
      antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
      Breast Cancer (TNBC), and whose tumor cells make a protein called glycoprotein NMB (gpNMB),
      which CDX-011 binds to. The study will also further characterize the safety of CDX-011
      treatment in this patient population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01997333</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>